Follistatin 344

Follistatin 344 (FS344) is a potent myostatin inhibitor that promotes muscle hypertrophy and strength by suppressing GDF-8 and activin pathways. It is explored in gene and peptide therapies for muscle-wasting diseases and performance enhancement. Human safety and regulatory pathways are still under evaluation.

• Binds to and inhibits myostatin (GDF-8)
• Disrupts activin receptor signaling to allow for muscle hypertrophy
• Promotes satellite cell activation and muscle fiber repair

• unit: mg

  low dose: 0.5

  frequency: Weekly

  high dose: 2

  standard dose: 1

  administration route: Subcutaneous (SQ)

• Inject 1–2 mg SubQ every 3–4 days for 4–6 weeks. Recommended 6+ week break afterward to avoid suppression feedback from prolonged myostatin blockade.

common: ["Injection site reactions"]

warnings: ["Potential adverse effects on reproductive hormone signaling","Limited human clinical safety data"]

long term: ["Unknown long-term impact on endocrine or cardiac systems"]

sequence: N/A for FS344

half life: Approx. 4 hours

degradation: Degraded by hepatic and tissue proteases

molecular weight: 38200

molecular formula: C1563H2529N419O448S8

tissue specificity: Preferentially acts on muscle and reproductive tissues

• The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs.preclinicalPMID 27787698 ↗
• Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series.clinicalPMID 32671599 ↗